22 Apr 2014 --- Novartis and GlaxoSmithKline, two leading global drug companies, have agreed to exchange assets and merge their consumer healthcare units. In the deal Novartis will acquire GSK’s cancer drug business for $16bn while GSK will acquire its vaccines division (excluding the flu unit) for $7.1bn.